156 patients will be excluded from the final analysis. These are patients with 6 months of treatment at the time of halt.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr